Pennsylvania Senate Bill SB691

Pennsylvania 2025-2026 Regular Session

• Introduced: 4/28/25
• Refer: 4/28/25

Caption

Establishing the Nonnarcotic Medication Substance Use Disorder Treatment Program; in organization and jurisdiction of courts of common pleas, providing for court assessments for substance use disorder treatment; in other criminal provisions, further providing for supervisory relationship to offenders; and, in Pennsylvania Board of Probation and Parole, further providing for supervisory relationship to offenders.

Impact

The bill's enactment will have significant implications for how Pennsylvania manages substance use disorder treatment among offenders, particularly those facing charges related to drug offenses. By encouraging the use of FDA-approved nonnarcotic medications and coordinating services through single county authorities, the bill aims to enhance the accessibility and effectiveness of rehabilitation efforts for individuals struggling with substance use disorders. This program will be funded through grants that the department may award to eligible county authorities, facilitating a more structured approach to delivering treatment services statewide.

Summary

Senate Bill 691, known as the Nonnarcotic Medication Substance Use Disorder Treatment Program, establishes a framework within Pennsylvania for providing substance use disorder treatment to offenders. It emphasizes the use of nonnarcotic medication-assisted treatment along with counseling and individualized care plans. The bill amends Titles 35, 42, and 61 of the Pennsylvania Consolidated Statutes to institutionalize this program under the Department of Drug and Alcohol Programs and sets forth the requirements for single county authorities to deliver such treatments effectively. Additionally, it allows courts to order assessments to determine the appropriateness of this type of treatment for offenders charged with drug-related offenses.

Sentiment

The sentiment surrounding SB 691 appears cautiously optimistic among proponents who view it as a progressive step towards better management of substance use issues within the criminal justice system. Supporters highlight the potential for reduced recidivism and improved health outcomes for offenders, aligning with broader public health goals. However, there are uncertainties regarding the funding and implementation logistics, which could temper enthusiasm. Critics may question the reliance on nonnarcotic medications and seek assurances that the program will not only focus on compliance but genuinely support recovery paths for offenders.

Contention

While the bill has gained traction, some points of contention remain regarding the effectiveness of nonnarcotic medications and the adequacy of resources to support the proposed treatment program. Stakeholders have voiced concerns about the potential gaps in supervision or support services that might undermine the program's objectives. The requirement for courts to adopt local assessment rules also raises questions about the standardization of treatment across different jurisdictions, which could lead to variations in care quality and accessibility for offenders based on their location.